|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.165 GBX | +6.91% |
|
+13.95% | +29.87% |
| Apr. 29 | Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director | CI |
| Apr. 02 | Immupharma jumps amid new IP strategy for P140 technology platform | AN |
British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals.
Avion and ImmuPharma will co-develop Lupuzor, including a new Phase III trail, and Avion will commercialise the drug exclusively in the United States, ImmuPharma said.
The British company said it would receive milestone payments of up to $70 million, comprising $5 million upon regulatory approval and up to $65 million based on sales targets.
(Reporting by Paul Sandle; editing by Kate Holton)
| 1st Jan change | Capi. | |
|---|---|---|
| +29.87% | 11.28M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
IMMUPHARMA PLC 
